NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
|Articles|November 8, 2011
Pfizer Outlines its Supply Strategy
John Kelly, vice-president of strategy and transitioning sites for Pfizer Global Supply, discusses the company's manufacturing and supply strategy and network.
Advertisement
John Kelly,
vice-president, strategy and transitioning sites,
Pfizer Global Supply
John Kelly, vice-president of strategy and transitioning sites for Pfizer Global Supply, discusses the company's manufacturing and supply strategy and network with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
Click
Advertisement
Related to this article
Jaenisch, Muraru, and Pandey join PharmTech's Cole to discuss FDA's generative AI paper, ARPA-H's SURPASS trials, and AI accountability.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Q&A: Patient-Centric Drug Development Should Start at Product Definition
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
5